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Heterozygous familial hypercholesterolemia (FH) is associ-
ated with an elevated lifetime burden of cardiovascular dis-
ease (CVD) (1). However, despite early exposure to elevated
plasma low-density lipoprotein cholesterol (LDL-C) levels,
there is heterogeneity at the onset of CVD in this popula-
tion. In addition to the presence of traditional risk factors
such as hypertension, smoking, and low plasma high-density
lipoprotein cholesterol levels, elevated lipoprotein(a) [Lp(a)]
levels have been associated in some (2,3), but not all (4,5),
studies with a greater prevalence of clinical and subclinical
CVD in patients with FH. However, these studies have been
limited by their cross-sectional or retrospective design and
also, with exception of 1 study (3), by the small number of
included subjects.See page 1982A recent patient-level meta-analysis of prospective studies,
as well as a large Mendelian randomization evaluation (6,7),
have established an independent association between Lp(a)
levels and the risk of CVD in the general population. This
might occur because Lp(a) is an LDL-like lipoprotein.
Nonetheless, Lp(a) carries an additional apolipoprotein,
apo(a) (8), that inhibits ﬁbrinolysis and may be the link
between lipid transport and coagulation systems in the
atherogenic process (8). In addition to its high cholesterol
content and antiﬁbrinolytic action, Lp(a) should also induce
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(9). Plasma Lp(a) levels are strongly determined genetically,
and production rates predominate over catabolism as their
main determinants (10,11).
In this issue of the Journal, Alonso et al. (12) elegantly
report on the association between Lp(a) levels as a predictor
of CVD and the interaction with the severity of LDLR
mutations in a well-characterized Spanish cohort of patients
with FH in SAFEHEART (Spanish Familial Hypercho-
lesterolemia Cohort Study). The investigators initially
found that Lp(a) levels were higher in patients with FH
than in their nonaffected normolipidemic relatives. The
investigators then showed that patients with FH and CVD
had higher Lp(a) levels than either unrelated subjects with
FH, but without CVD, or normolipidemic relatives without
CVD. When subjects carrying the most frequent null and
defective LDLR mutations were compared, those with null
mutations had higher Lp(a) levels and a greater incidence of
CVD. Moreover, for those with LDLR null mutations, who
are in theory those with the highest risk of CVD due to
more elevated LDL-C levels from birth (1), Lp(a) levels
were higher in those with CVD. Also, subjects with null
mutations and Lp(a) levels >50 mg/dl, a value associated
with an elevated risk of CVD in the general population (13),
had the shortest free survival time from onset of CVD.
Finally, Lp(a) levels were independently associated with
CVD in the whole FH cohort.
This is a well-performed proof-of-concept study with a
large number of study subjects and is carefully analyzed. All
subjects with FH had a molecular diagnosis, and the non-
affected control subjects were their relatives. Of course, the
cross-sectional nature of the study precludes the ﬁnal
conclusion that an elevated Lp(a) level is indeed an inde-
pendent risk factor for CVD in patients with FH, as it is for
the general population (6,7).However, this study advances the
knowledge in the ﬁeld and adds important information
regarding a possible interaction between more severe LDLR
mutations and higher Lp(a) levels with a greater risk of CVD.
The lack of a role of LDLR in catabolism of Lp(a) is
intriguing, because this lipoprotein encloses apoB-100, the
natural binder of LDLR within its particle. Studies in both
subjects with homozygous FH (10) and transgenic mice (11)
failed to show reduced clearance from plasma of Lp(a) in the
absence of the LDLR. Indeed, statins that increase hepatic
LDLR expression do not show a signiﬁcant effect on Lp(a)
plasma levels (13). However, the role of a putative inﬂuence
of the LDLR on Lp(a) catabolism cannot be discarded
because subjects with homozygous FH present with higher
Lp(a) levels than both subjects with heterozygous FH and
normolipidemic subjects (14). The ﬁnding of the current
study (12) of higher Lp(a) levels in those with more frequent
LDLR null mutations suggests that this association might
not be attributable to chance only. However, one cannot
discard that those with more severe LDLR mutations can
also inherit greater apo(a) production capacity and therefore
have higher Lp(a) plasma levels.
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1991Recent evidence showing that antibodies that block
PCSK9 (proprotein convertase subtilisin/kexin type 9), a
protein that facilitates the degradation of LDLR in the liver,
reduce, not only LDL-C and apoB-100, but also Lp(a) (15)
plasma levels in patients with FH adds more controversy to
the matter. Should we also blame LDLR for higher Lp(a)
plasma levels and possibly a greater risk of CVD in subjects
with FH?
Notwithstanding biological controversies, the study
by Alonso et al. (12) suggests an interaction between the
more severe LDLR mutations and Lp(a) as a cause of CVD
in patients with FH. The prospective phase of SAFE-
HEART is needed to conﬁrm the ﬁndings of the current
evaluation.
Despite the strong evidence between increased Lp(a)
plasma levels and a greater risk of CVD in the general
population (6,7) and the suggested elevated risk of CVD
shown in the study by Alonso et al. (12) and studies from
others in subjects with FH (2,3), there is very little evidence
that a reduction in Lp(a) level prevents CVD (16). It is
important to show that newer therapies that reduce Lp(a)
levels in addition to LDL-C levels (15,17) will prevent
CVD.
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